LMEN: Ulipristal (Esmya) for pre-operative and intermittent treatment of moderate to severe uterine fibroids – license extension

· London Medicines Evaluation Network

Esmya (ulipristal acetate 5mg tablets) was launched in April 2012 for pre-operative treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age. In May 2015, the license was further extended to allow intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age.This review presents the evidence which supports this licence variation.

NOTE: The content of this resource has not been updated since the publication date. Some information may be out of date and links to other documents or website may not work.

New MedicinesObstetrics and gynaecologySurgeryUlipristal

Attachments